Sanofi (SNY)
equity · Nasdaq
- Last 30 days
- 2 mentions · 2 episodes
- Last 90 days
- 2 mentions · 2 episodes
Stance shows how speakers talked about the asset, not investment advice. Figures and views are speaker claims; verify them against the original audio and primary sources.
Mentions over time
bullishbearishmixedneutral
2026-08-24
2026-08-31
2026-09-07
2026-09-14
2026-09-21
2026-09-28
2026-10-05
2026-10-12
2026-10-19
2026-10-26
2026-11-02
2026-11-09
2
2026-11-16
Recent mentions
The East-West Bio Brief ·
Daily, Sat 14 Nov: FDA decision day for ivonescimab, Akeso's lung cancer bispecific
Ning neutral
“Together with a $50 million private placement from Sanofi, it expects to raise $225 million before costs, according to its company press release.”
The East-West Bio Brief ·
Daily, Thu 12 Nov: A Shanghai pill wins FDA approval, after China said yes first
Unidentified speaker (speaker_0) neutral
“And Sanofi has agreed to buy $50 million of shares in a private placement alongside the offering.”
Claims about this asset
Unidentified speaker (UNKNOWN) says: Recursion has partnerships with Roche, Genentec, and Sanofi.
How to verify: Search Recursion Pharmaceuticals' investor relations website or SEC filings (e.g., 8-K or 10-K) for partnership agreements with Roche, Genentec, and Sanofi. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Recursion Pharmaceuticals: Can AI Turn Biology Into Medicines? - $RXRXPrimary source
Often mentioned with
No other assets in the same segments yet.
Podcasts that cover it most
- The East-West Bio Brief · 2 mentions